Premium
Evaluation of l‐(2‐chloroethyl‐3‐4‐methylcyclohexyl)‐l‐nitrosourea (methyl‐CCNU, NSC 95441) versus combined imidazole carboxamide (NSC 45388) and vincristine (NSC 67574) in palliation of disseminated malignant melanoma
Author(s) -
Ahmann David L.,
Hahn Richard G.,
Bisel Harry F.
Publication year - 1974
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197403)33:3<615::aid-cncr2820330304>3.0.co;2-f
Subject(s) - medicine , lomustine , vincristine , vomiting , nitrosourea , toxicity , nausea , combination therapy , gastroenterology , pharmacology , oncology , chemotherapy , cyclophosphamide
Methyl‐CCNU (l‐(2‐chloroethyl‐3‐4‐methylcyclohexyl)‐l‐nitrosourea; NSC 95441) was compared to the combination of imidazole carboxamide (NSC 45388) and vincristine (NSC 67574) as treatment in 38 patients with disseminated malignant melanoma. Objective regressions were observed in 5 of 19 patients who received methyl‐CCNU as primary therapy and in 4 of 19 who received the combination. Thus far, no patient has had therapeutic benefit from either treatment program as secondary therapy. The toxicity in 28 patients who received methyl‐CCNU included myelosuppression, with leukocyte counts <3,000/mm 3 in 10 and platelet counts <100,000/mm 3 in 11, compared to 5 patients with leukocyte counts <3,000/mm 3 4 with platelet counts < 100,000/mm 3 among 22 patients receiving the combination. Nausea and vomiting were common with the combination although hospitalization was not necessary because of this. Neurologic toxicity was seen only in patients receiving the combination; no other appreciable toxicity was observed in those receiving methyl‐CCNU.